Menu

Potential Sanofi-Insmed Deal: Analysts Split on Financial Strain Versus Pipeline Gains
📰

Potential Sanofi-Insmed Deal: Analysts Split on Financial Strain Versus Pipeline Gains

Top Stories Feed·Vandana Singh·about 3 hours ago
#MNVBrtOG
#benzinga#sanofi#dupixent#insmed#deal
Long article (518 words) — no AI summary yet.
Reading 0:00
15s threshold

French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is reportedly exploring a potential acquisition of Insmed Inc. (NASDAQ:INSM) .

As per a Thursday Bloomberg report, the potential acquisition comes as Sanofi seeks new growth opportunities to reduce its reliance on blockbuster drug Dupixent.

Preparing For Sanofi’s Post-Dupixent Trajectory

Belén Garijo , Sanofi CEO, said, " We are confident about our ability to pursue our strong commercial and financial performance in the short and medium term. The whole organization is focused on managing Sanofi’s post-Dupixent trajectory over the next decade."

Read Also: Sanofi Must Set Record Straight on Rival Flu Shot Under EU Antitrust Deal

"Our priority is to protect earnings through Dupixent’s loss of exclusivity. We have already begun taking action to improve R&D productivity.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.